Gossamer Bio News

12 Health Care Stocks Moving In Thursday's After-Market Session

GainersTevogen Bio Holdings (NASDAQ:TVGN) shares rose 51.8% to $1.29 during Thursday's after-market session. The company's market cap stands at $212.3 million. Fresh2 Group (NASDAQ:FRES) stock rose 10

BenzingaApr 25 16:32 ET

12 Health Care Stocks Moving In Friday's After-Market Session

GainersLongeveron (NASDAQ:LGVN) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by

BenzingaApr 5 16:31 ET

Gossamer Bio Coverage Assumed by Wedbush at Outperform

Gossamer Bio Coverage Assumed by Wedbush at Outperform

Dow JonesApr 5 05:07 ET

Express News | Wedbush Assumes Gossamer Bio at Outperform, Announces Price Target of $4

Moomoo 24/7Apr 5 04:57 ET

Express News | Piper Sandler Maintains Overweight on Gossamer Bio, Maintains $15 Price Target

Moomoo 24/7Mar 27 12:43 ET

Buy Rating Affirmed on Gossamer Bio With Promising Seralutinib Prospects in PAH Treatment Landscape

TipRanksMar 27 09:55 ET

Gossamer Bio (GOSS) Receives a Buy From Piper Sandler

TipRanksMar 27 07:06 ET

Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Gossamer Bio (GOSS) and Vor Biopharma (VOR)

TipRanksMar 21 09:00 ET

13 Best Biotech Stocks To Buy Under $20

Yahoo FinanceMar 13 07:07 ET

Piper Sandler Sticks to Its Buy Rating for Gossamer Bio (GOSS)

TipRanksMar 13 06:55 ET

Gossamer Bio Welcomes New Board Members, Enhances Leadership

TipRanksMar 12 16:13 ET

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to Its Board of Directors

PDF Version SAN DIEGO--(BUSINESS WIRE)--Mar. 12, 2024-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutin

Gossamer BioMar 12 00:00 ET

Barclays Keeps Their Hold Rating on Gossamer Bio (GOSS)

TipRanksMar 11 02:45 ET

Gossamer Bio Is Maintained at Buy by Goldman Sachs

Gossamer Bio Is Maintained at Buy by Goldman Sachs

Dow JonesMar 6 11:47 ET

Goldman Sachs Maintains Buy on Gossamer Bio, Lowers Price Target to $8

Goldman Sachs analyst Paul Choi maintains Gossamer Bio with a Buy and lowers the price target from $9 to $8.

Analyst UpgradesMar 6 11:36 ET

Gossamer Bio Price Target Maintained With a $6.00/Share by Wedbush

Gossamer Bio Price Target Maintained With a $6.00/Share by Wedbush

Dow JonesMar 6 11:21 ET

Express News | HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target

Moomoo 24/7Mar 6 08:44 ET

Strong Buy Rating on Gossamer Bio Amidst Seralutinib's Promising Trials and Solid Financials

TipRanksMar 6 07:55 ET

Gossamer Bio Earns 'Buy' Rating From Analyst Citing Progress in Seralutinib Trials and Strategic Market Expansion

TipRanksMar 5 20:15 ET

Maintained Buy Rating on Gossamer Bio Amidst Anticipated Phase 3 PROSERA Trial Results

TipRanksMar 5 18:15 ET